FDA Brief

Warning letters Drugs

FDA warning letter to

Yusef Manufacturing Laboratories, LLC

High riskIssued Feb 8, 2022Posted Apr 12, 2022Division of Pharmaceutical Quality Operations IV

FDA warned Yusef Manufacturing Laboratories over serious CGMP violations in its OTC drugs and hand sanitizers, including untested ethanol.

What happened

FDA inspected the Clearfield, UT drug manufacturing facility from September 20 to 24, 2021. Investigators found that the company accepted ethanol active ingredient based only on color, odor, appearance, and a supplier certificate of analysis, without testing it for identity or methanol before using it in hand sanitizer. FDA also found incomplete out-of-specification investigations, inadequate laboratory controls, missing process validation, and insufficient stability data.

What FDA found

  1. Failed to test incoming components for identity and relied on supplier certificates of analysis without validating supplier test results.

    21 CFR 211.84(d)(1) and (2)
  2. Failed to thoroughly investigate failing assay results and released sunscreen after retesting without a full root-cause investigation or effective corrective action.

    21 CFR 211.192
  3. Lacked suitable analytical and microbiological test methods, including testing hand sanitizer for assay, identity, and methanol before release.

    21 CFR 211.160(b)
  4. Failed to validate manufacturing processes to show reproducible and controlled production.

    21 CFR 211.100(a)
  5. Lacked adequate stability data to support three-year expiration dates.

    21 CFR 211.166(a)

What FDA wants

FDA tells the company to correct the violations promptly and respond in writing within 15 working days with corrective action plans, risk assessments, and other requested information. FDA also strongly recommends engaging a CGMP consultant.

Who should pay attention

  • companies using ethanol in OTC drugs or hand sanitizers
  • brands that buy OTC sunscreens or sanitizers from contract manufacturers
  • quality teams managing supplier COA verification and OOS investigations

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk